Berenberg Bank Reiterates Buy Rating for Spire Healthcare Group (LON:SPI)

Berenberg Bank restated their buy rating on shares of Spire Healthcare Group (LON:SPI) in a research note published on Tuesday morning, Marketbeat reports. Berenberg Bank currently has a GBX 300 ($3.96) price target on the stock.

Spire Healthcare Group Price Performance

Shares of LON SPI opened at GBX 234 ($3.09) on Tuesday. The stock has a 50 day moving average of GBX 248.66 and a two-hundred day moving average of GBX 245.19. The stock has a market cap of £944.94 million, a P/E ratio of 3,342.86, a P/E/G ratio of 1.06 and a beta of 0.97. Spire Healthcare Group has a twelve month low of GBX 207 ($2.73) and a twelve month high of GBX 270.50 ($3.57). The company has a current ratio of 0.70, a quick ratio of 0.74 and a debt-to-equity ratio of 169.51.

Insider Activity

In related news, insider Justin Ash purchased 21,100 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average price of GBX 236 ($3.12) per share, for a total transaction of £49,796 ($65,780.71). Corporate insiders own 34.71% of the company’s stock.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.